^
Association details:
Biomarker:MTAP deletion
Cancer:Ovarian Cancer
Drug:AMG 193 (PRMT5 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

AMG 193 Effective in Multiple Tumor Types

Published date:
10/17/2023
Excerpt:
In a phase I trial of the MTA-cooperative PRMT5 inhibitor AMG 193, five of 39 patients with advanced MTAP-deleted solid tumors who had scans following initial treatment experienced partial responses...tumor types-esophageal, pancreatic, renal cell, gallbladder, and ovarian Sertoli-Leydig cell cancer.
DOI:
10.1158/2159-8290.CD-NB2023-0079